TSS, Inc. to Ring Nasdaq Closing Bell on January 24

Stock Information for Oncotelic Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncotelic Therapeutics Inc

TSS, Inc. Unveils 2026 Trends in High Performance Computing and Data Center Technology
TSS Reports First Quarter 2025 Revenue of $99.0 Million, Up 523% EPS of $0.12, Up from $0.00
TSS, Inc. to Host First Quarter 2025 Financial Results Conference Call on May 15, 2025
TSS, Inc. to Participate at the 20th Annual Needham Technology, Media, & Consumer Conference
TSS Revenue Grows 172% to a Record $148.1 Million in FY 2024; Increases EPS to $0.24, Up from $0.00 in 2023
TSS, Inc. to Host Fourth Quarter and Year-End Financial Results Conference Call on March 27, 2025
TSS, Inc. to Participate in the 37th Annual ROTH Conference
OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.